The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.
Sep 2026· Cancer Letters· pp.
218852
· 0 citations· 34 references
Medicine
TL;DR
Investigation of the critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin in promoting SCLC metastasis concluded that Vim+ CTECs serve as a key driver of tumor metastasis in SCLC.
Abstract
Aggressive progression of small-cell lung cancer (SCLC) is orchestrated by a dynamic tumor microenvironment (TME). However, profiling this ecosystem remains a major constraint. The critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin (i.e. Vim+ CTECs amid Endo-MT process) in promoting SCLC metastasis was systematically investigated in this study. Large cohorts of 142 treatment-naïve SCLC patients were prospectively enrolled in the current multicenter study. Patients were subjected to the first-line platinum-based chemotherapy alone or combined with immunotherapy or radiotherapy as indicated. Both Vim- and Vim+ CTECs were longitudinally co-detected at baseline (t0), after two cycles (t1), and post-complete treatment (t2). A high baseline CTEC count (≥ 15/6 mL) correlated with a higher incidence of liver metastasis and a lower initial disease control rate. Positive detection of Vim+ CTECs (t0) was also significantly associated with liver metastasis. Multivariate analysis identified post-treatment Vim+ CTECs (t1-2) as an independent prognostic factor for both inferior progression-free survival (PFS) and overall survival (OS). The metastasis-promoting function of endothelial vimentin was further validated using in vivo liver metastasis mouse models and in vitro vimentin-knockdown endothelial cell lines. Mechanistically, endothelial vimentin was essential for promoting SCLC cell proliferation, migration, liver metastasis in vivo, and invasion in vitro, which were abrogated by vimentin knockdown. Vim+ CTECs serve as a key driver of tumor metastasis in SCLC. Detection of Vim+ CTECs constitutes a novel paradigm for real-time risk stratification and outcome prediction.
No strong association was observed with SPC, whereas low TMB (compared with moderate TMB) was associated with the competing endpoint of death without developing SPC, whereas low TMB (compared with moderate TMB) was associated with the competing endpoint of death without developing SPC.
M. Gauthier, Maryam Karimi, S. Michiels et al.· Frontiers in Oncology· 0 citations
In LARC, CRT reshapes the type and amount of immune cell contents, and the effects on certain immune populations are associated with tumor regression and clinical outcome.
Francesca Negri, L. Bottarelli, L. Gnetti et al.· JCO Precision Oncology· 0 citations
BACKGROUND
The relationship between the tumor microenvironment, comprising programmed cell death-1 ligand-1 (PD-L1), CD8-positive tumor-infiltrating lymphocytes (CD8+TIL), and FOXP3+TIL, in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and its clinicopathological featur...
Megumi Mizutani, Yoshiya Matsumoto, C. Ohe et al.· Clinical Lung Cancer· 0 citations
Circulating tumor cells (CTCs) are closely associated with the progression of hepatocellular carcinoma (HCC). However, the clinical value of CTC detection in patients receiving systemic therapy for advanced HCC remains to be fully elucidated. A total of 125 patients with advanced HCC who underwent systemic therapy were...
Jiang-Min Zhou, Hui-Fang Xiong, Hong-Hao Zhou et al.· Frontiers in Oncology· 0 citations
High CD103⁺ tumor-infiltrating lymphocyte infiltration may be associated with improved overall survival in bladder cancer, particularly in muscle-invasive bladder cancer patients undergoing surgery with adjuvant chemotherapy.
Eduardo Germano Teixeira, L. A. Torres, Maria L. R. Defante et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.